Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRC102 (methoxyamine) is a small-molecule inhibitor of base excision repair (BER) that potentiates the cytotoxicity of DNA-damaging chemotherapies, such as pemetrexed, by binding to chemotherapy-induced abasic sites in DNA and preventing their repair. This leads to accumulation of DNA damage and increased cancer cell death. Pemetrexed is an antifolate antineoplastic agent that inhibits enzymes involved in folate metabolism and DNA synthesis, thereby blocking cancer cell proliferation. The combination has been studied primarily for advanced solid tumors, including non-small cell lung cancer (NSCLC), malignant mesothelioma, and salivary gland tumors. Clinical trials have shown that the combination can be administered safely with evidence of antitumor activity[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TRC102 + pemetrexed.